ImmuCell Reports Q3 2025 Financial Results with Improved Gross Margin and Net Operating Income

ImmuCell Corporation reported its financial results for the third quarter and nine-month period ending September 30, 2025, revealing a notable shift in performance compared to the previous fiscal period. The company generated product sales of $5.5 million for the third quarter, a decrease of 8% from $6.0 million in the same quarter of 2024. However, for the nine-month period, sales increased by 7% to $20.0 million, up from $18.7 million in the prior year. The gross margin for the third quarter improved significantly to 43% from 26% year-over-year, while the nine-month gross margin rose to 43% from 27%, reflecting enhanced operational efficiency and cost management.

The company’s net operating income for the third quarter was $20,075, a substantial recovery from a net operating loss of $574,894 in the same quarter of 2024. For the nine-month period, ImmuCell reported a net operating income of $1.7 million, compared to a loss of $2.3 million in the prior year. This turnaround was attributed to a $3.4 million increase in gross margin and a reduction in operating expenses. Despite these gains, the company recorded a net loss of $139,748 for the third quarter, an improvement from a loss of $701,690 in the same period last year, while net income for the nine-month period was $1.8 million, contrasting with a loss of $2.7 million in 2024.

Operationally, ImmuCell has made strides in addressing previous contamination issues that affected production. The company reported a backlog reduction to less than $100,000 as of June 30, 2025, down from $9.1 million in March 2024, indicating improved inventory availability and production capacity. The First Defense® product line continues to dominate sales, accounting for 99% of total product sales, with the company also expanding its offerings to include a functional feed platform. The company is actively exploring international market opportunities and has initiated a research agreement with the Mayo Clinic to investigate potential human health applications for its Nisin technology.

In terms of financial position, ImmuCell's total assets increased to $45.7 million as of September 30, 2025, up from $45.1 million at the end of 2024. The company reported a cash balance of $3.9 million, a slight increase from $3.8 million at the end of the previous year. Total stockholders' equity rose to $29.8 million, reflecting an 8% increase from $27.5 million. The company has also made strategic changes in its leadership, appointing a new CEO effective November 1, 2025, which may further influence its operational direction and growth strategy.

Looking ahead, ImmuCell remains focused on achieving FDA approval for its Re-Tain® product, which is expected to enhance mastitis management in dairy cows. The company is also evaluating potential partnerships to offset product development costs and is committed to maintaining its operational improvements while navigating market challenges. The management anticipates that existing cash reserves, along with projected gross margins from ongoing sales, will be sufficient to meet working capital and capital expenditure requirements for at least the next 12 months.